PRESS RELEASE DUBLIN, Aug. 10, 2015 /PRNewswire/ –Allergan plc , a respected global pharmaceutical company, announced that it has finished the acquisition of Oculeve today, a development-stage medical gadget company focused on developing novel remedies for dry eyes disease. Under the conditions of the agreement, Allergan obtained Oculeve for a $125 million upfront payment and commercialization milestone payments linked to Oculeve's lead advancement program, OD-01 USA pharmacy . The contract also includes the acquisition of yet another earlier-stage dry eye device development program.

Can be a pharmaceutical business advancing the advancement of treatments for fungal infections, malaria, tuberculosis, malignancy, diabetes, Pneumocystis carinii pneumonia and tropical illnesses, including African sleeping sickness and leishmaniasis.. All patients in research clear parasite that causes African sleeping sickness Immtech International has announced that all 30 patients taking part in the concluded Stage IIb extended dose program arm of its clinical trial of DB289 for treating African sleeping sickness cleared the parasite that triggers African sleeping sickness within the treatment period, without significant adverse results reported.